Research Paper Volume 12, Issue 17 pp 17694—17712

Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells

Figure 5. Targeting MALAT1/SF2/ARv7 axis increased the efficacy of Enz to further suppress the DocR_22Rv1 cells growth. (A, B) The growth curve of DocR1_CWR22Rv1 (A) and DocR2_CWR22Rv1 (B) cells in response to Enz treatment after targeting MALAT1/SF2/ARv7 axis with either ARv7-shRNA (upper middle), SF2-shRNA (lower left), or MALAT1-siRNA (lower middle). Right panels are quantification of survival rate under Enz treatment at Day 6. (CH) The protein level of (C, E) fAR and ARv7, 6 days growth curves (D and left) and statistics (D and F right) of Day 6 (right) of (C, D) DocR1_CWR22Rv1 after DMSO, 10 μM Enz, or 5 μM ASC-J9® treatment for 24 hrs and (E, F) DocR2_CWR22Rv1 after DMSO, 10 μM Enz, or 5 μM ASC-J9® treatment for 24 hrs. (G, H) DocR2_CWR22Rv1 protein levels (G) growth curves after DMSO, 10 μM Enz or 3 μg/ml Cisplatin (CIS) treatment (H) for 24 hrs. Results are mean ± SD compared to controls *p<0.05; **p<0.01; ***p<0.001.